Matthew Emmens's Net Worth
$97.1 Million
Who is Matthew Emmens?
Matthew Emmens has an estimated net worth of $97.1 Million. This is based on reported shares across multiple companies, which include BRISTOL MYERS SQUIBB CO, VERTEX PHARMACEUTICALS INC / MA, and INCYTE CORP.
SEC CIK
Matthew Emmens's CIK is 0001298332
Past Insider Trading and Trends
2017 was Matthew Emmens's most active year for acquiring shares with 5 total transactions. Matthew Emmens's most active month to acquire stocks was the month of January. 2011 was Matthew Emmens's most active year for disposing of shares, totalling 4 transactions. Matthew Emmens's most active month to dispose stocks was the month of January. 2021 saw Matthew Emmens paying a total of $226,249.98 for 3,628.383 shares, this is the most they've acquired in one year. In 2011 Matthew Emmens cashed out on 65,735 shares for a total of $2,656,131.85, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
BRISTOL MYERS SQUIBB CO (BMY) Snapshot price: $48.6
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
VERTEX PHARMACEUTICALS INC / MA (VRTX) Snapshot price: $468
Executive Chairman
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.12% | -10.85K |
$41.76 | -$453,096.00 | 200.87K |
Nov 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
| -20.93% | -56.00K |
$37.78 | -$2,115,742.00 | 211.6K |
Scheduled
|
Feb 6
| ||
Form 4
| +21.42% | 47.2K |
$0.01 | $472.01 | 267.6K |
Feb 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 13
| |||
Form 4
| -4.23% | -9.73K |
$55.51 | -$540,389.85 | 220.4K |
May 25
| |||
Form 4
| +25.91% | 47.2K |
$0.01 | $472.01 | 229.41K |
Feb 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 14
| |||
Form 4
| +34.96% | 47.2K |
$0.01 | $472.01 | 182.21K |
Feb 4
| |||
Form 4
|
∞
| 134.13K |
$0.01 | $1,341.29 | 134.13K |
Feb 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
INCYTE CORP (INCY) Snapshot price: $60.96
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
| No matching records found | |||||||||